News

Sunshine Biopharma Announces Pricing of $5.0 Million Private Placement Priced At-the-Market

MONTREAL, May 12, 2023 (GLOBE NEWSWIRE) -- Sunshine Biopharma Inc. (NASDAQ: “SBFM”), a pharmaceutical company offering and researching life-saving medicines…

2 years ago

Spectral Medical Announces First Quarter Results and Provides Corporate Update

New Trial Sites Enroll 60% of New Patient Enrollments Since the Beginning of April Tigris Patient Enrollment at 58 Patients…

2 years ago

Longeveron Inc. Provides Corporate Update and Reports First Quarter 2023 Financial Results

-- New long-term survival data disclosed from ELPIS I trial of Lomecel-BTM for Hypoplastic Left Heart Syndrome; Data reinforce potential…

2 years ago

SCYNEXIS Reports Closing of Exclusive License Agreement with GSK for BREXAFEMME® (Ibrexafungerp Tablets)

SCYNEXIS is receiving an upfront payment of $90 million with future performance-based milestone payments of up to $503 million and…

2 years ago

Vyant Bio Announces Last Day of Trading on Nasdaq and Filing of Form 15 for Voluntary Nasdaq Delisting and SEC Deregistration

CHERRY HILL, N.J., May 12, 2023 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio” or “Company”) (Nasdaq: VYNT) is a…

2 years ago

Adaptive Biotechnologies to Participate in the 2023 RBC Capital Markets Global Healthcare Conference

SEATTLE, May 12, 2023 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that…

2 years ago

Gain Therapeutics Reports First Quarter 2023 Financial Results and Business Update

Successfully completed GLP toxicology studies for lead program GT-02287 in GBA1 Parkinson’s diseaseCompany is on track to submit application for…

2 years ago

Landos Biopharma Provides Business Update and Reports First Quarter 2023 Results

NEXUS Phase 2 Clinical Trial of NX-13 for Ulcerative Colitis Initiated NEXUS Top-line Results Planned for Q4 2024 Sufficient Cash…

2 years ago

MoonLake Immunotherapeutics Reports First Quarter 2023 Financial Results and Provides a Business Update

MoonLake Immunotherapeutics Reports First Quarter 2023 Financial Results and Provides a Business Update Capital Markets Day held in April highlighted…

2 years ago

Psychedelic Science 2023 Announces Sessions and Select Featured Speakers for the Therapy and Practitioners Tracks for June Conference

Dr. Rachel Yehuda to Lead Discussions on Therapeutic Application of Psychedelics Additional Featured Speakers Include Dr. Julie Holland, Dr. Carl…

2 years ago